Join to View Full Profile
330 brookline aveBoston, MA 02215
Phone+1 617-667-3753
Dr. Porter is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Massachusetts General Hospital/Beth Israel Deaconess Medical Center/Brigham and Women's HospFellowship, Dermatology, 2016 - 2017
Roger Williams Medical CenterResidency, Dermatology, 2016
St Elizabeth's Medical Center/Lemuel Shattuck HospitalInternship, Transitional Year, 2013 - 2014
Drexel University College of MedicineClass of 2013- Roger Williams Medical CenterChief Residency, Dermatology
Certifications & Licensure
MA State Medical License 2013 - 2028
NH State Medical License 2024 - 2024
RI State Medical License 2014 - 2016
American Board of Dermatology Dermatology
Clinical Trials
- Effect of Sclerotherapy on Fistulas and Sinus Tracts in Hidradenitis Suppurativa
- Secukinumab for NLD (Cosentyx) in Patients With Necrobiosis Lipoidica Diabeticorum (NLD) Start of enrollment: 2019 Apr 03
- Study to Assess Efficacy and Safety of Dupilumab in the Treatment of Keloids Start of enrollment: 2023 Jan 13
Publications & Presentations
PubMed
- Symposium on Hidradenitis Suppurativa Advances 2025 Proceedings.Claire S Chung, Kenan Kherallah, Nazrin Ashina, Gabriela E Beraja, Anuj Budhiraja
Dermatology and Therapy. 2026-06-01 - Prospective cohort study comparing hidradenitis suppurativa-associated atrophic scar treatments: Fractional carbon dioxide laser versus fractional radiofrequency micro...G Ege Eskibozkurt, Soahum Bagchi, Martina Porter, Sepideh Ashrafzadeh, Thao-Mary Tran
Journal of the American Academy of Dermatology. 2026-01-01 - 6 citationsDelphi Panel for the Development of Diagnostic Criteria for Metastatic Cutaneous Crohn Disease: A Consensus Statement.Joseph Ebriani, Karla Santiago-Soltero, Ellen E Anshelevich, Rahul S Dalal, Bridget Shields
JAMA Dermatology. 2025-06-01
Press Mentions
Phase 3 Data Put Povorcitinib on HS RadarSeptember 22nd, 2025- Incyte Announces New 24-Week Phase 3 Data from the STOP-HS Clinical Trial Program of Povorcitinib in Hidradenitis Suppurativa at EADV 2025September 17th, 2025
Elderly Patients with Nonmelanoma Skin Cancer More Likely to Go UntreatedSeptember 24th, 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
